Ipratropium bromide/salbutamol
Combination drug
From Wikipedia, the free encyclopedia
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).[1][4][5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[1]
| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Trade names | Combivent, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601063 |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Common side effects include sore throat, muscle cramps, and nausea.[1] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[1] Safety in pregnancy is unclear.[6][1]
The combination was approved for medical use in the United States in 1996.[7] It is available as a generic medication.[4] In 2023, it was the 181st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9]
